CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genzyme Biosurgery is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genzyme Biosurgery
500 Kendall Street
Phone: (617) 252-7500p:617 252-7500 Cambridge, MA  02142  United States Ticker: GZBX GZBX

This company is no longer actively traded on any major stock exchange.

Business Summary
Genzyme Biosurgery develops and commercializes implantable biotechnology products. The Company, which is one of the three divisions of Genzyme Corporation, is focused on three medical areas: orthopaedic disease and injury, serious heart disease and improving the outcomes of surgery. Within these areas, Genzyme Biosurgery's portfolio includes a range of marketed biotherapeutics, biomaterials and medical devices, with many more under development. Genzyme Biosurgery bolstered its leadership in the orthopaedic market in 2001 with two marketed products that serve the osteoarthritis and sports medicine segments. These products have great, untapped growth potential to help people who would otherwise be forced to severely limit their activities due to the pain of osteoarthritis or damaged cartilage.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
---Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
--Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Henri A.Termeer 55
President Earl M.Collier, Jr. 57 12/1/2000 12/1/2000
Chief Financial Officer, Senior Vice President MichaelWyzga 46

General Information
Number of Employees: 5,600 (As of 12/31/2002)
Outstanding Shares: 40,686,433 (As of 6/30/2003)
Shareholders: 6,452
Stock Exchange: NASD
Federal Tax Id: 061047163
Fax Number: (617) 252-7600


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, November 24, 2019